Immupharma Share Discussion Threads

[nobbygnome] 24/6/2021 07:30

The experimental evidence is so clear that not enough drug is being used. I don't want to go through it all again but any trained scientist who looks at all the data together would come to the same conclusion. It's bleedin obvious....

It appears the FDA have belatedly realised this.....

[david gruen] 24/6/2021 07:29

"Do you not have to wait until the market opens before you can close your short?"

Not for a 50p per point spreadbet.

[nobbygnome] 24/6/2021 07:28

>> David

You would be surprised. I talked at length with someone directly involved in the company and he took my proposals very seriously. Unfortunately Zimmer et al are blinkered so of course didn't seriously consider any changes.

[base7] 24/6/2021 07:27

Perhaps if the FDA response is positive a bidder will emerge who will accelerate the approval process & look at our treatments as niche products, thereby putting long suffering shareholders out of their misery & providing we shorter term investors with a gracious ( & hopefully profitable exit)

[nobbygnome] 24/6/2021 07:26

It's not that positive......

[the stinger] 24/6/2021 07:24

Short closed today. Unexpected positive news

[david gruen] 24/6/2021 07:23

Unfortunately drug development companies don't tend to pick up dosage recommendations from the ADVFN bulletin board.

[david gruen] 24/6/2021 07:22

Appreciate your perspective Nobby.

[nobbygnome] 24/6/2021 07:21

Well slow progress is being made but slow is most definitely the word! So if the trial starts at the end of this year by my reckoning the earliest Lupuzor could be on the market is 2025 and that's if Avion execute the trial well. Their complete inexperience in this field doesn't bode well for that.

Of course that all assumes that they get positive feedback from the FDA. When they realise the drug is all gone in a few hours they may want to try some higher or more frequent dosing. Now who suggested that about 4 years ago.....

[david gruen] 24/6/2021 07:19

24/06/2021 7:00am
UK Regulatory (RNS & others)

Immupharma (LSE:IMM)
Intraday Stock Chart

Thursday 24 June 2021

Click Here for more Immupharma Charts.
TIDMIMM

RNS Number : 9181C

Immupharma PLC

24 June 2021

RNS: RELEASE 24 JUNE 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

FDA to agree on the Lupzuor(TM) PK study via a written response to "Type C" meeting as Avion prepares for international Phase 3 trial

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that its US Lupuzor(TM) partner, Avion Pharmaceuticals ("Avion") has received a positive response from the US Food & Drug Administration ("FDA") for a "Type C" meeting. The FDA has advised that they do not require a formal face to face meeting and will provide their written response to Avion approximately by the end of July 2021.

As noted in our previous announcement of 9 February, this is the final guidance meeting at which the FDA will review the proposed methodology of the pharmacokinetic ("PK") study. This study was requested by the FDA as part of the new optimised international Phase 3 trial of Lupuzor(TM) in systemic lupus erythematosus ("SLE"), a potentially life-threatening autoimmune disease.

ImmuPharma will provide an update as soon as Avion has received the written response from the FDA and advised ImmuPharma of the next steps and timetable towards commencing the Phase 3 trial this year.

Commenting on the announcement, Tim Franklin, COO of ImmuPharma said :

"We continue to acknowledge the FDA's support following constructive meetings and feedback this year with our partner Avion. ImmuPharma and Avion are fully committed to commencing the Lupuzor(TM) Phase 3 trial in Lupus patients this year. Again, we reiterate Lupuzor's(TM) unique mechanism of action and robust safety profile to date, which we believe will position Lupuzor(TM) as a first line therapy to many Lupus sufferers globally."

[the stinger] 17/6/2021 16:19

We shall see 1ultimate, and as we wait for 4p theres new lows each day.

[1ultimate] 16/6/2021 18:22

You’ve been for waiting 4p for a very long time, you ain’t getting it tw@t. You’ll get 40p and your short will be 🔥 🔥 lol

[the stinger] 16/6/2021 15:41

Still waiting for under 4p ... won't be long

[brad44] 15/6/2021 10:12

giving financial advice again are we ken..tut tut

[ken chung] 09/6/2021 08:58

Sell before it goes to 0p fair value.

[the stinger] 08/6/2021 15:55

TP now 2p, this coy is so pointless , I not sure why it's actually listed apart from paying extremely high salaries and to dilute PI's each year.

[the stinger] 08/6/2021 13:44

Everyone bailing out before the big drop! All sells and it's constant.

[the stinger] 07/6/2021 21:09

They may well of done yes, however has it actually got this anywhere since! Well it has fallen to 8p I suppose, good achievement eh!

Must be all that news flow

[sicilian_kan] 07/6/2021 20:10

That isn't really true. They funded an entire P3 themselves.

[the stinger] 07/6/2021 14:33

The company has no prospects!!, All/Any cash is spent on wages!

[sicilian_kan] 07/6/2021 14:22

Actually, I think the company has better prospects without Zimmer - albeit he was very good for the company in many ways - and it is interesting to see that the share price has not fallen since his departure, indeed at the time there was a small rise.